Regeneron Pharmaceuticals, Inc. (REGN)

572.36
NASDAQ
Prev Close 569.37
Day Low/High 565.39 / 573.01
52 Wk Low/High 441.00 / 686.62
Exchange NASDAQ
Shares Outstanding 106.96B
Market Cap 60.90B
P/E Ratio 19.71
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: Why Hasn't the Government Pushed for Mass Vaccination?

Jim Cramer: Why Hasn't the Government Pushed for Mass Vaccination?

Incompetence, omissions and even outright lies have categorized this federal attempt to 'stem' the pandemic.

Pfizer's Charts Suggest a Strong Rally Ahead

Pfizer's Charts Suggest a Strong Rally Ahead

Here are our latest price targets.

Look No Further Than AbbVie If You Need a Defensive/Dividend Type Name

  AbbVie has been a Sarge fave for a long time. Sarge has been rewarded for trusting this firm's management when they acquired Allergan as a means toward replacing expected reductions in cash flows moving forward as the firm's patents for winder dru...

Jim Cramer: The Drug Cos. Are at Full Strength

Jim Cramer: The Drug Cos. Are at Full Strength

We're seeing a group move in pharma right now, so let's sort it out, pill by pill.

Updating Our Bullish Strategy for Regeneron Pharmaceuticals

Updating Our Bullish Strategy for Regeneron Pharmaceuticals

Here are our new price targets.

Jim Cramer: Let's Saw Through That Home Depot Reaction

Jim Cramer: Let's Saw Through That Home Depot Reaction

We just got hit with a two-by-four, but in your daze, don't confuse this retailer's report with the entire market and economy.

Jim Cramer: The Fortunes Have Been Restored for Regeneron and Abbott

Jim Cramer: The Fortunes Have Been Restored for Regeneron and Abbott

The tables have turned, their stocks have been up, and I think they go higher still.

Abbott Labs Is Poised to Break Out to New Highs

Abbott Labs Is Poised to Break Out to New Highs

Let's check out the charts of ABT.

Jim Cramer: To Every Market Sector, Turn, Turn, Turn

Jim Cramer: To Every Market Sector, Turn, Turn, Turn

To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...

For Now, Moderna Is an Options Play For Me

For Now, Moderna Is an Options Play For Me

The shares are only trading at 17 times forward earnings, and might not be fully valued just yet.

Regeneron Reaches a Price Target: Let's Take Another Look

Regeneron Reaches a Price Target: Let's Take Another Look

Another review of the REGN charts is in order.

Jim Cramer: Monday's Market Is One of the Most Mind-Blowing I've Seen

Jim Cramer: Monday's Market Is One of the Most Mind-Blowing I've Seen

Buyers make or break companies with their voting or buying or betting. Somedays it's all that matters.

Jim Cramer: I Warned You That Betting Against Science Is a Mug's Game

Jim Cramer: I Warned You That Betting Against Science Is a Mug's Game

And I was right, and the cynics were wrong. Here's why that matters more than ever now.

Following Up on Our Regeneron Recommendation

Following Up on Our Regeneron Recommendation

Here's what traders should consider doing now.

ARKK Under Pressure, Peloton, Vaccine Moral Dilemma, Charting the Nasdaq

ARKK Under Pressure, Peloton, Vaccine Moral Dilemma, Charting the Nasdaq

The fund is at a key spot technically, and there is real fear that if this spot cracks, what looks like a stretch of rough rapids could become a waterfall.

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'

Jim Cramer: We've Got a Boom ... and a Bust

Jim Cramer: We've Got a Boom ... and a Bust

Let's look at this impossible move on the market -- and why health care could be coming off life support.

Here's How I'd Treat Regeneron

Here's How I'd Treat Regeneron

It looks like it's time to go long Regeneron, as the charts have improved.

There's No Rush to Purchase Regeneron Stock

There's No Rush to Purchase Regeneron Stock

The charts are not particularly attractive at this point in time.

Jim Cramer: It's Time for Clear COVID Rules That Make Sense

Jim Cramer: It's Time for Clear COVID Rules That Make Sense

Outside of the pro sports world, it seems like amateur hour with regard to protocols.

Regeneron Raised to Outperform at BMO

Jim Cramer: Here Are the Biden Stocks

Jim Cramer: Here Are the Biden Stocks

As power has changed hands in the White House, we can expect these names -- and themes -- to benefit.

Jim Cramer: If Government Gets Its Act Together, This Is What Could Happen

Jim Cramer: If Government Gets Its Act Together, This Is What Could Happen

The vaccine rollout has been bungled and the nation's in crisis, but you can either dwell on the negativity or look to ingenuity and opportunity. Here's where I see the latter.

Regeneron Raised to Buy at Benchmark

How to Play Emergent BioSolutions Right Now

How to Play Emergent BioSolutions Right Now

A correction in EBS could soon set up an attractive opportunity.

Looking at 4 Potential Buy Setups This Week

Looking at 4 Potential Buy Setups This Week

Let's review the charts of DBX, FSLY, REGN, and SPCE.

The Week That Was, Q4 Earnings Expectations, Key Investor and Healthcare Events

The Week That Was, Q4 Earnings Expectations, Key Investor and Healthcare Events

This Friday several banks begin the unofficial kickoff of 'earnings season'.

Covid Vaccine Distribution, Jobs, Stimulus Package, Brexit Terms, Investor Days

Covid Vaccine Distribution, Jobs, Stimulus Package, Brexit Terms, Investor Days

Most important come Inauguration Day is the seamless transition of leadership over 'Operation Warp Speed'.